Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 11/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.39 |
| ▸ | FNTA | P49354 | 4/20 | 0.34 |
| ▸ | FNTB | P49356 | 4/20 | 0.34 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.34 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13274527 | 0.92 | MET (0.39) | METNQO2FNTAFNTBPGGT1B | |
| SCHEMBL13274895 | 0.91 | MET (0.44) | METNQO2FNTAFNTBPGGT1B | |
| SCHEMBL13274995 | 0.91 | MET (0.42) | METNQO2 | |
| SCHEMBL2221042 | 0.91 | MET (0.41) | METNQO2FNTAFNTBPGGT1B | |
| SCHEMBL13275648 | 0.89 | MET (0.40) | METNQO2FNTAFNTBPGGT1B | |
| SCHEMBL2351533 | 0.88 | MET (0.39) | METNQO2FGFR3KDR | |
| SCHEMBL13274649 | 0.84 | MET (0.45) | METNQO2ALKBH1 | |
| SCHEMBL13275082 | 0.83 | CYP11B1 (0.39) | METNQO2FGFR3KDR | |
| SCHEMBL13275105 | 0.82 | MET (0.46) | METNQO2ALKBH1 | |
| SCHEMBL13274873 | 0.82 | MET (0.43) | METFGFR3KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | claimed |
| WO-2011084402-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-07-14 | — | — | WO | claimed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2012-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264735-A1 | TYROSINE KINASE INHIBITORS | ABL1, MET, ERBB2 | MET 2/4885NQO2 1984/4885FNTA 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.